

References

I-236

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Hayes, Inc. Hayes Hayes, Inc. Hayes Health Prognosis Overview. Casimersen for Duchenne Muscular Dystrophy. Lansdale, PA: Hayes, Inc.; 09/2020.
3. Kuntz N, Wagner K, East L, etc. Casimersen treatment in eligible patients with Duchenne muscular dystrophy: Safety, tolerability, and pharmacokinetics over 144 weeks of treatment. *Neuro Disorders*. 2020;30(S1):S130-S131.
4. Amondys 45 (Casimersen), injections [package insert]. Sarepta Therapeutics, Inc. Cambridge, MA. Revised 02/2021.
5. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Casimersen.
6. Micromedex DrugDex Compendium®. 2021. Casimersen.
7. [Casimersen] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated [2021].
8. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.